Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices.

ABSTRACT:

Background

Cyclophosphamide (CYC) is an inactive alkylating agent that transforms the alkyl radicals into other molecules and is used in combination with systemic corticosteroids in the treatment of many childhood rheumatic diseases, such as systemic lupus erythematosus (SLE), and ANCA-associated vasculitis (AAV). In recent years, rituximab (RTX), a B-cell-targeting anti-CD20 monoclonal antibody, has emerged as a new alternative treatment modality over CYC for induction therapy of childhood-onset rheumatic diseases. Clinicians adopt different practices for using CYC particularly in relation to indications, posology, pre-treatment laboratory work-up, post-treatment follow-up, and screening pre- and post-treatment vaccination status. This study aimed to evaluate the principles and ap

SUBMITTER: Gezgin Yildirim D 

PROVIDER: S-EPMC11895381 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature